20/20 BioLabs Mulls Merger, Acquisition, Licensing, JV, Commercial Collaborations Across East Asia Under Its Roll-Up Strategy
20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic
20/20 BioLabs is exploring different ways to grow its business in Asia—like teaming up with other companies or buying smaller ones. When companies look for these kinds of partnerships, it usually means they're trying to expand, but nothing is decided yet.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.